Last updated on April 19, 2014 at 9:20 EDT

Latest Douglas Jabs Stories

2013-07-16 20:21:28

PETACH TIKVA, Israel, July 16, 2013 /PRNewswire/ -- OphthaliX Inc. (OTC BB: OPLI), announced today the submission of a Phase II study protocol of its drug candidate, CF101, for the treatment of uveitis. The Phase II study will be conducted in Europe and Israel and will investigate the efficacy and safety of CF101 in 45 patients with active, sight-threatening, noninfectious intermediate or posterior uveitis, who will be treated with either CF101 or a placebo for a period of six...